Abacavir and lamivudine combination

Bibliography

• James J. FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides. AIDS Treat News 2004;23(403):1
   Google Scholar
• Calza L, Rosseti N, Biagetti C, Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. AIDS Patient Care STDS 2008;22(10):276-7
   Google Scholar
• Panel on antiretroviral guidelines for adults and adolescents. DDHS guidelines for the treatment of HIV infected adults and adolescents. Available from: http://www.aidsinfo.nih.gov ., November 2008. [Accessed 14 June 2009]
   Google Scholar
• Society(EACS) TEAC. European AIDS Clinical Society(EACS). Guidelines for the clinical management and treatment of HIV infectede adults in Europe. Available from: http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines%2012mai09.pdf, October 2008. [Accessed 5 October 2009]
   Google Scholar
• Hammer SM, Eron JJJr, Reiss P, Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300(5):555-70
   PubMed Web of Science ®Google Scholar
• Epzicom Precribing Information. Available from: http://usgskcom/products/assets/us_epzicompdf 2009 [Accessed 14 June 2009]
   Google Scholar
• Update of the Drug Resistance Mutations in HIV-1: December 2008. Available from: http://wwwiasusaorg/resistance_mutations/mutations_figurespdf 2008 [Accessed 14 June 2009]
   Google Scholar
• Moyle GJ, DeJesus E, Cahn P, Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005;38(4):417-25
   PubMed Web of Science ®Google Scholar
• Gathe JC Jr, Ive P, Wood R, SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18(11):1529-37
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23(12):1547-56
   PubMed Web of Science ®Google Scholar
• Albrecht H. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202. AIDS Clin Care 2008;20(4):28
   Google Scholar
• Cohen CJ, Kubota M, Brachman PS, Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study. Pharmacotherapy 2008;28(3):314-22
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004;39(7):1038-46
   PubMed Web of Science ®Google Scholar
• Young B, Squires K, Patel P, First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 2008;22(13):1673-5
   PubMed Web of Science ®Google Scholar
• Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24(10):1502-14
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-79
   PubMed Web of Science ®Google Scholar
• Calza L, Rosseti N, Biagetti C, Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative. Int J STD AIDS 2009;20(4):276-7
   PubMed Web of Science ®Google Scholar
• Tripuraneni NS, Smith PR, Weedon J, Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature. AIDS Patient Care STD 2004;18:6
   Google Scholar
• Bellini C, Keiser O, Chave JP, Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009;10(1):12-8
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622):1417-26
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Cotte L, , and the Clicnical Epi Group of the French Hosp Database on HIV. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal. Abstract 43LB
   Google Scholar
• Cooper DA, Bloch M, Humphries A, , on behalf of the STEAL study group. Simplification with fixed-dose tenofoviremtricitabineor abacavir-lamivudine in adult with suppressed HIV replication (the STEAL study): a randomized, open-label, 96 week, non-inferior trial. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal
   Google Scholar
• Benson C, Ribaudo H, Zheng E, , and the ACTG A5001/ALLRT Protocol Team. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal
   Google Scholar
• Brothers CH, Hernandez JE, Cutrell AG, Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009;51(1):20-8
   PubMed Web of Science ®Google Scholar
• Bedimo R, Westfall A, Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. 5th IAS Conference in HIV Pathogenesis, Treatment and Prevention: July 19-22, 2009. Cape Town; 2009
   Google Scholar
• Lichtenstein K, Buckner K, Armon C, The HOPS Investigators. Low CD4 cel count is an important risk factor for cardiovascular disease in the US HIV Outpatient Study (HOPS). XVII International AIDS Conference, August 3-8, 2008. Mexico City; 2008
   Google Scholar
• SMART Study Group. CD4+ count– guided interruption of antiretroviral treatment. NEJM 2006;355:2283-96
   PubMed Web of Science ®Google Scholar
• McComsey G, Smith K, Patel P, Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: The HEAT Study. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009. Montreal
   Google Scholar
• Palella F, Gange S, Elion R, Inflammatory markers among abacavir and non-abacavir recipients in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal
   Google Scholar
• Martinez E, Larrousse M, Perez I, No evidence for recent abacavir/lamivudine use in promoting inflammation, endothelial dysfunction, hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the BICOMBO randomized clinical trial (ISRCTN6189). 5th IAS Conference in HIV Pathogenesis, Treatment and Prevention: July 19-22, 2009. Cape Town; 2009
   Google Scholar
• Shikuma C, Zheng E, Ribaudo H, , and AIDS Clinical Trials Group A5095. 96 week effects of suppressive efavirenz containing ART, bacavir, and sex on hsCRP in ACTG A5059. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009. Montreal; 2009
   Google Scholar
• Satchell C, O' Connor E, Peace A, Platelet hyper-reactivity in HIV-1-infected patients on abacavir-containing ART.16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal
   Google Scholar
• Hsue P, Wu Y, Schnell A, Association of abacavir and HIV disease factors with endothelial function in patients on long-term suppressive ART. 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal
   Google Scholar